ArticleHealth affairs scholar2023
Recent modifications to the US methadone treatment system are a Band-Aid-not a solution-to the nation's broken opioid use disorder treatment system.
Article in Health affairs scholar, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data.Addiction (Abingdon, England) · 2025Trial
- Attributes of higher- and lower-performing hospitals in the Consult for Addiction Treatment and Care in Hospitals (CATCH) program implementation: A multiple-case study.Journal of substance use and addiction treatment · 2025Trial
- "In My Community, if You're an Addict, People Don't Just Look Down on You for the Drugs, but for Being Black, Too": Black and Latine Methadone Patients' Experiences Around Addiction, Methadone Treatment, and Intersectional Stigma.Journal of racial and ethnic health disparities · 2026Article
- Impact of enhanced practices on opioid overdose deaths: A community-based modeling approach.Addiction (Abingdon, England) · 2026Article
- Implementing Three-Day Methadone in a Low-Threshold Bridge Clinic: Impact of OTP Referral Pathways on Treatment Retention.Research square · 2026Article
- Envisioning a Humane and Accessible US Methadone Treatment System: Generating Policy and Practice Recommendations From the Liberate Methadone Movement.Substance use & addiction journal · 2026Article
- De-implementation of inequitable methadone policy and treatment: lessons learned from COVID-19 to support a more just methadone treatment system in the United States.Frontiers in public health · 2026Review
- Perspectives on prescribed safer supply programs among people who inject drugs in Baltimore, Maryland: A mixed methods study among individuals highly affected by drug toxicity.The International journal on drug policy · 2025Article
- "Now that I'm here, I actually have the stability and the time to really think about stuff like that": Perspectives on medications for opioid use disorder in low-threshold harm reduction housing.Journal of substance use and addiction treatment · 2025Article
- Population-Level Health Benefits and Harms Associated With Buprenorphine/Naloxone vs Methadone.JAMA network open · 2025Article
- Veterans Health System Leader and Clinician Perspectives on Expanding Access to Methadone Treatment for Opioid Use Disorder.Journal of addiction medicine · 2025Article
- Hospital Provider's Perspectives on MOUD Initiation and Continuation After Inpatient Discharge.Journal of general internal medicine · 2025Article
- Medication experiences in the treatment of opioid use disorders: Insights from Reddit.Addiction (Abingdon, England) · 2025Article
- Substance-induced mental disorders and discontinuation of medication for opioid use disorder.Drug and alcohol dependence · 2025Article
- State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset.Addiction (Abingdon, England) · 2025Article
- Drug treatment and support service utilization amidst the COVID-19 pandemic among people who inject drugs in Baltimore, Maryland: An interrupted time-series analysis, 2015-2022.The International journal on drug policy · 2025Article
- Toward a Consensus on Strategies to Support Opioid Use Disorder Care Transitions Following Hospitalization: A Modified Delphi Process.Journal of general internal medicine · 2025Article
- "I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.Journal of substance use and addiction treatment · 2025Article
- Article
- Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study.Drug and alcohol dependence · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For 5 decades, US federal regulations have segregated methadone treatment for opioid use disorder from the rest of the health care system, confining its availability to specialty treatment programs that are highly regulated. These regulations have led to severe shortages in the availability of methadone and grave underutilization of this lifesaving medication despite a worsening overdose crisis. In this commentary, we discuss current barriers to methadone in the US opioid treatment system and how recent changes to federal regulations fall short of the reforms needed to significantly expand access to this treatment. Instead, we propose the urgent need to expand methadone to mainstream health care settings by allowing for office-based prescribing and pharmacy dispensing of methadone, the norm in many other developed countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.